6505--Notice of Intent to Sole Source Amarillo VAHCS Blood Support Services

Active

Contract Opportunity

Special Notice Notice of Intent to Award a Sole Source Procurement

The Thomas E. Creek VA Health Care System located in Amarillo, Texas has an ongoing need for the supply of blood and blood products from the Oklahoma Blood Institute (OBI). The activity requires a continuous source for various transfusions as well as services related to transfusion screening services on a daily and 24/7 emergency basis.

The names and/or description of the supplies are included at the bottom of this document.

Delivery Address:
Department of Veterans Affairs
Amarillo VAHCS
6010 Amarillo Blvd West
Amarillo, TX 79106-1991

The proposed sole source procurement will be made by an Indefinite Delivery Indefinite Quantity (IDIA) contract with the Oklahoma Blood Institute (OBI).

The requesting activity has submitted a sole source justification request that states that vendor is the only vendor that can provide the necessary products and services to be a direct replacement of the currently provided blood products. Market research has not found an alternate approved vendor that can provide all the required linearity supplies for the services.

This notice is not to be considered a request for quotations or proposals. No contract will be awarded on the basis of offers received in response to this notice; however, all responsible sources may submit a capability statement, proposal or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 5 days from the publication of this notice, a contract will be issued to CAP without any further notice.

The anticipated statutory authority permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.
DESCRIPTION
ANNUAL ESTIMATES
01A: ABO/Rh (per specimen)
11
02A: Direct Antiglobulin Test (Coombs Test) - single
11
04A: Cold agglutinin low temperature screen
11
04B: Antibody Elution and Red Cell Panel
11
04E: Antibody Absorption and Red Cell Panel
11
04F: Additional Red Cell Antibody Panel
11
11: Washing (per unit) - RBC
1
12: Freezing/Deglycerolization (per unit)
1
12B: Compatibility Testing (per unit) - AHG
20
14: CMV Negative Blood Product (Available Inventory)
1
15A: Fetal Hemoglobin Screen (rosette test)
1
16B: Leukoreduced Red Blood Cells
200
16I: Leukoreduced Red Blood Cells - Irradiated
11
34: Washing (per unit) - Platelet - plus plasma
1
34A: Washing (per unit) - Platelet - plus plasma-A
1
40: AFFP ( 250 + 25ml) x 2 Apheresis Derived
1
40-2: AFFP ( 250 + 25ml) x 1 Apheresis Derived
11
40CCP: COVID-19 Convalescent Plasma, (CCP) ~200 ml dose, High Titer
1
40PED: AFFP (100 + 10ml) x 1 Apheresis Derived
1
42: FFP-WBD 1 x 250ml (250 + 25 ml) Whole Blood Derived
1
42HR: FP-24 (Frozen 11
42PED: FP-24 (Frozen 1
44: Cryoprecipitated AHF
1
44PD: Cryoprecipitate Pool of 5 (includes pooling fee)
11
44PD10: Cryoprecipitate Pool of 10 (includes pooling fee)
1
50: Plasma AHF Removed
1
61: Leukoreduced Apheresis Platelets
20
61I: Leukoreduced Apheresis Platelets - Irradiated
11
96: Autologous Collection (per component)
1
97: Directed Collection (per component)
1
99C: Aliquot Bags, Pediatric (attached, per set)
1
DI3: Wra Antigen Type
1
EXT: Extraction of DNA for red cell phenotype by molecular method
10
FC10: Pooled Fibrinogen Complex 1.0, Psoralen Treated - 740 mg Fibrinogen (mean)
1
FC15: Pooled Fibrinogen Complex 1.5, Psoralen Treated - 1,457 mg Fibrinogen (mean
1
FC20: Pooled Fibrinogen Complex 2.0, Psoralen Treated - 2,220 mg Fibrinogen (mean)
1
FC30: Pooled Fibrinogen Complex 3.0, Psoralen Treated - 3,117 mg Fibrinogen (mean)
1
FC40: Pooled Fibrinogen Complex 4.0, Psoralen Treated - 3,700 mg Fibrinogen (mean)
1
FY1: Fya Antigen Type
11
FY2: Fyb Antigen Type
1
JK1: Jka Antigen Type
11
JK2: Jkb Antigen Type
1
K1: K Antigen Type
11
K2: k Antigen Type
1
K3: Kpa Antigen Type
1
L03: Antibody Screen
11
L04: Antibody Identification (includes ABO/Rh, antibody screen, comprehensive DAT, red cell panel, written consultation report, medical consultation as needed.)
11
L07: Antibody Titer
1
L08: After hours Tech call Fee: Surcharge per patient request
11

DESCRIPTION
ANNUAL ESTIMATES
L12: Compatibility Testing (per unit) - Immediate Spin
1
L13: Pretreatment of Serum (eg. DTT, Rest, Plasma Neutralization, Urine Inhibition, Lewis Neutralization, P1 Neutralization)
1
L14: Pretreatment of RBCs (eg. DTT, CDP, EGA, Ficin, Density Gradient Separation, Neocytes)
11
L15: Fetal Hemoglobin Stain (Kliehauer Betke)
1
L30: Blood Component Preparation for each order to cover the preparation of the blood component for transport and transfusion.
Â
11
L31: Sample resubmission
1
L32: Cancellation Fee charged when an order is cancelled once a driver is dispatched.
1
L35: Shipping Fee - Specimen Transport or Reagents Shipped Without Blood
1
L89: Sickle Cell Testing (per unit)
1
LE1: Lea Antigen Type
1
LE2: Leb Antigen Type
1
LVDS: Platelet Large Volume Delayed Sampling Fee
11
MS1: M Antigen Type
11
MS2: N Antigen Type
11
MS3: S Antigen Type
1

End of Document

Attachments/Links